Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Sitagliptin vs Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease
This study is currently recruiting participants.
Study NCT00509236 Information provided by Merck
First Received: July 27, 2007 Last Updated: October 16, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Renal Disease, End-Stage
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
Kidney Diseases
Kidney Failure, Chronic
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Kidney Failure
Metabolic Diseases
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Interventions listed in this trial
sitagliptin phosphate
Comparator: glipizide
Comparator: Placebo (unspecified)
Additional drug interventions recognized in this trial
Glipizide
Sitagliptin
More general drug interventions related to this trial
Dipeptidyl-Peptidase IV Inhibitors
Enzyme Inhibitors
Hypoglycemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sponsors listed in this trial
Merck
Back to top of Main Content
